Haleos LabsNSE:HALEOSLABS -0.50%72 Net Margin % is 0.58% as of Mar. 2026, which is 88% below its 10-year median of 4.99. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,123.78 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 937 Biotechnology companies, Haleos Labs ranks better than 76.2% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Haleos Labs's Net Income for the
three
months ended in Mar. 2026 was ₹4 Mil. Haleos Labs's Revenue for the
three
months ended in Mar. 2026 was ₹751 Mil. Therefore, Haleos Labs's net margin for the quarter that ended in Mar. 2026 was 0.58%.
The historical rank and industry rank for Haleos Labs's Net Margin % or its related term are showing as below:
NSE:HALEOSLABS'
s Net Margin % Range Over the Past 10 Years
Min: 3.04 Med: 4.99 Max: 7.29
Current: 5.19
NSE:HALEOSLABS's Net Margin % is ranked better than 76.2% of 937
companies
in the Biotechnology industry
Industry Median: -88.29
vs NSE:HALEOSLABS: 5.19
Haleos Labs (NSE:HALEOSLABS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Haleos Labs Net Margin % Related Terms
Haleos Labs Net Margin % Historical Data
* Premium members only.
The historical data trend for Haleos Labs's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:HALEOSLABS vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Haleos Labs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's Net Margin % distribution charts can be found below:
* The bar in red indicates where Haleos Labs's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleos Labs (NSE:HALEOSLABS) has a Net Margin % of 0.58% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Haleos Labs and its competitors. This is 88% below median its historical median of 4.99. Over the past decade, Haleos Labs' Net Margin % has ranged from 3.04 to 7.29. According to the industry distribution chart, Haleos Labs ranks #223 out of 937 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Haleos Labs' Net Margin % too high?
Haleos Labs' current Net Margin % of 0.58% is 88% below median its 10-year median of 4.99. Over the past 10 years, this metric has ranged from a low of 3.04 to a high of 7.29. Based on the distribution chart, Haleos Labs ranks #223 out of 937 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #223 out of 937 companies for Net Margin %. This places Haleos Labs in the top 24% of its industry — outperforming the majority of peers. Historically, Haleos Labs' own Net Margin % has ranged from 3.04 to 7.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Haleos Labs and its competitors. Haleos Labs's current Net Margin % is 0.58%, which is 88% below median its own 10-year median of 4.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,123.78, compared to a current price of ₹1,612.30 — trading 43.5% above its estimated fair value. The current Net Margin % is 0.58%, which is 88% below median its 10-year median of 4.99. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current Net Margin % is 0.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,612.30 is trading 43.5% above its estimated GF Value™ of ₹1,123.78.
GuruFocus considers Haleos Labs to be Significantly Overvalued.
Key valuation signals for NSE:HALEOSLABS:
Net Margin %: 0.58% (88% below median its 10-year median of 4.99)
GF Value™: ₹1,123.78 vs. price of ₹1,612.30 (43.5% above fair value)
No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score
Get the complete analysis for NSE:HALEOSLABS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HALEOSLABS has been successfully added to your 
